A1 Refereed original research article in a scientific journal

Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria




AuthorsEgevad Lars, Delahunt Brett, Iczkowski Kenneth A, van der Kwast Theo, van Leenders Geert JLH, Leite Katia RM, Pan Chin-Chen, Samaratunga Hemamali, Tsuzuki Toyonori, Mulliqi Nita, Ji Xiaoyi, Olsson Henrik, Valkonen Masi, Ruusuvuori Pekka, Eklund Martin, Kartasalo Kimmo

PublisherWiley

Publication year2023

JournalHistopathology

Journal name in sourceHISTOPATHOLOGY

Journal acronymHISTOPATHOLOGY

Volume82

Issue6

First page 837

Last page845

Number of pages9

ISSN0309-0167

eISSN1365-2559

DOIhttps://doi.org/10.1111/his.14867

Web address https://onlinelibrary.wiley.com/doi/10.1111/his.14867

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/178865454


Abstract

Aims

There is strong evidence that cribriform morphology indicates a worse prognosis of prostatic adenocarcinoma. Our aim was to investigate its interobserver reproducibility in prostate needle biopsies.

Methods and results

A panel of nine prostate pathology experts from five continents independently reviewed 304 digitised biopsies for cribriform cancer according to recent International Society of Urological Pathology criteria. The biopsies were collected from a series of 702 biopsies that were reviewed by one of the panellists for enrichment of high-grade cancer and potentially cribriform structures. A 2/3 consensus diagnosis of cribriform and noncribriform cancer was reached in 90% (272/304) of the biopsies with a mean kappa value of 0.56 (95% confidence interval 0.52-0.61). The prevalence of consensus cribriform cancers was estimated to 4%, 12%, 21%, and 20% of Gleason scores 7 (3 + 4), 7 (4 + 3), 8, and 9-10, respectively. More than two cribriform structures per level or a largest cribriform mass with >= 9 lumina or a diameter of >= 0.5 mm predicted a consensus diagnosis of cribriform cancer in 88% (70/80), 84% (87/103), and 90% (56/62), respectively, and noncribriform cancer in 3% (2/80), 5% (5/103), and 2% (1/62), respectively (all P < 0.01).

Conclusion

Cribriform prostate cancer was seen in a minority of needle biopsies with high-grade cancer. Stringent diagnostic criteria enabled the identification of cribriform patterns and the generation of a large set of consensus cases for standardisation.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 21:36